Friday February 10, 2012
Home > Newsletters > Directors Daily Briefing > Boardroom News > SEC Charges Seattle-Area Biotech Company With Fraudulently Hyping Stem Cell Breakthrough

SEC Charges Seattle-Area Biotech Company With Fraudulently Hyping Stem Cell Breakthrough

The Securities and Exchange Commission today charged a Bothell, Wash.-based biotechnology company, its former CEO, and its former Chief Scientific Officer for falsely telling investors that the company’s cutting-edge stem cell technology had been proven successful and was headed for human trials.

September 8, 2009
Share ...
  • email
  • Google Bookmarks
  • Facebook
  • Twitter
  • Digg
  • LinkedIn
  • RSS
Print Print
The Securities and Exchange Commission today charged a Bothell, Wash.-based biotechnology company, its former CEO, and its former Chief Scientific Officer for falsely telling investors that the company's cutting-edge stem cell technology had been proven successful and was headed for human trials.

Comments are closed.